Skip to main content
. 2017 Jan 19;116(4):432–440. doi: 10.1038/bjc.2016.419

Figure 3.

Figure 3

Estimates of PFS and OS.(A) PFS from week 12 in patients with melanoma who were randomly assigned to continue treatment with cabozantinib (n=13) or placebo (n=13). (B) PFS from first dose in all patients with metastatic melanoma (N=77) and in patients with uveal melanoma (n=23). (C) OS in all patients with metastatic melanoma (N=77) and in patients with uveal melanoma (n=23). HR=hazard ratio.